Product Categories

Erlotinib HCl

Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.

Catalog No.S1023

12 Reviews 21 Product Citations

: Tel: +1-832-582-8158[email protected]

Erlotinib HCl Chemical Structure
Molecular Weight: 429.90

Validation & Quality Control

Product Citations(21)

Customer Reviews(12) in vivo invitation

Quality Control & MSDS

Related Compound Libraries

Erlotinib HCl is available in the following compound libraries:

Inhibitor Library (96-well) Kinase Inhibitor Library (96-well) FDA Approved Drug Library (96-well) Chemotherapeutic Agent Library (96-well) Chemical Library (96-well) Tyrosine Kinase Inhibitor Library (96-Well) Cambridge Cancer Compound Library(96-well)

Product Information

Compare EGFR Inhibitors

Research Area
Research Area

Cat.No.	Product Name	Solubility (25°C)
S1023	Erlotinib HCl	<1 mg/mL	3 mg/mL	<1 mg/mL
S1025	Gefitinib (Iressa)	<1 mg/mL	89 mg/mL	4 mg/mL
S1028	Lapatinib Ditosylate (Tykerb)	<1 mg/mL	185 mg/mL	<1 mg/mL
S1011	Afatinib (BIBW2992)	<1 mg/mL	97 mg/mL	15 mg/mL
S1143	AG-490	<1 mg/mL	59 mg/mL	6 mg/mL
S2111	Lapatinib	<1 mg/mL	100 mg/mL	<1 mg/mL
S1167	CP-724714	<1 mg/mL	94 mg/mL	94 mg/mL
S2727	Dacomitinib (PF299804,PF-00299804)	<1 mg/mL	19 mg/mL	<1 mg/mL
S2728	AG-1478 (Tyrphostin AG-1478)	<1 mg/mL	25 mg/mL	13 mg/mL
S1019	CI-1033 (Canertinib)	<1 mg/mL	2 mg/mL	9 mg/mL
S1194	CUDC-101	<1 mg/mL	20 mg/mL	<1 mg/mL
S2150	Neratinib (HKI-272)	<1 mg/mL	2 mg/mL	<1 mg/mL
S1173	WZ4002	<1 mg/mL	13 mg/mL	<1 mg/mL
S1392	Pelitinib (EKB-569)	<1 mg/mL	13 mg/mL	<1 mg/mL
S2192	AZD8931	<1 mg/mL	40 mg/mL	<1 mg/mL
S2185	AST-1306	<1 mg/mL	124 mg/mL	<1 mg/mL
S2752	Arry-380	<1 mg/mL	114 mg/mL	<1 mg/mL
S1079	PD153035 HCl	<1 mg/mL	0.5 mg/mL	<1 mg/mL
S2755	ARRY334543	<1 mg/mL	6 mg/mL	<1 mg/mL
S2867	WHI-P154	<1 mg/mL	75 mg/mL	<1 mg/mL
S1179	WZ8040	<1 mg/mL	96 mg/mL	3 mg/mL
S2205	OSI-420	2 mg/mL	83 mg/mL	<1 mg/mL
S1056	BMS-599626 (AC480)	<1 mg/mL	113 mg/mL	20 mg/mL
S1486	AEE788 (NVP-AEE788)	<1 mg/mL	88 mg/mL	<1 mg/mL
S2784	TAK-285	<1 mg/mL	110 mg/mL	54 mg/mL
S2826	Desmethyl Erlotinib (CP-473420)	<1 mg/mL	11 mg/mL	5 mg/mL
S8009	AG 18 (Tyrphostin 23)	<1 mg/mL	37 mg/mL	37 mg/mL
S1170	WZ3146	<1 mg/mL	93 mg/mL	<1 mg/mL
S2895	Tyrphostin 9 (SF 6847)	<1 mg/mL	56 mg/mL	56 mg/mL
S2922	Icotinib	<1 mg/mL	78 mg/mL	7 mg/mL
S7039	PD168393	<1 mg/mL	74 mg/mL	<1 mg/mL

Combination Therapy

Dr. Antonino Maria Sparta demonstrates a breakthrough in leukemia research by utilizing two inhibitors produced by Selleck Chemicals.

Product Description

Biological Activity Protocol Chemical Information Customer Reviews Product Citations Tech Support & FAQs

Biological Activity

Description	Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.
Targets	HER1/EGFR
IC50	2 nM ^[1]
In vitro	Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells. ^[1] Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. ^[2] Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. ^[3] The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. ^[4] Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition. ^[5]
In vivo	At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. ^[1] Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate. ^[5]
Clinical Trials	Erlotinib HCl plus BKM120 has entered in a phase II clinical trial in the treatment of non small cell lung cancer.
Features

Protocol(Only for Reference)

Kinase Assay: ^[1]

Kinase assays	96-well plates are coated by incubation overnight at 37 °C with 100 μL per well of 0.25 mg/mL PGT in PBS. Excess PGT is removed by aspiration, and the plate is washed 3 times with washing buffer (0.1% Tween 20 in PBS). The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3), containing 125 mM sodium chloride, 24 mM magnesium chloride, 0.1 mM sodium orthovanadate, 20 μM ATP, 1.6 μg/mL EGF, and 15 ng of EGFR, affinity purified from A431 cell membranes. Erlotinib HCl in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 minutes at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with washing buffer. Phosphorylated PGT is measured by 25 minutes of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with washing buffer. The colonmetric signal is developed by addition of TMB Microwell Peroxidase Substrate, 50μL per well, and stopped by the addition of 0.09 M sulfuric acid, 50 μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no back ground in wells without AlP, EGFR, or PGT and is proportional to the time of incubation for 10 minutes.

Kinase assays

96-well plates are coated by incubation overnight at 37 °C with 100 μL per well of 0.25 mg/mL PGT in PBS. Excess PGT is removed by aspiration, and the plate is washed 3 times with washing buffer (0.1% Tween 20 in PBS). The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3), containing 125 mM sodium chloride, 24 mM magnesium chloride, 0.1 mM sodium orthovanadate, 20 μM ATP, 1.6 μg/mL EGF, and 15 ng of EGFR, affinity purified from A431 cell membranes. Erlotinib HCl in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 minutes at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with washing buffer. Phosphorylated PGT is measured by 25 minutes of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with washing buffer. The colonmetric signal is developed by addition of TMB Microwell Peroxidase Substrate, 50μL per well, and stopped by the addition of 0.09 M sulfuric acid, 50 μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no back ground in wells without AlP, EGFR, or PGT and is proportional to the time of incubation for 10 minutes.

Cell Assay: ^[2]

Cell lines	A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 cells
Concentrations	30 nM-20 μM
Incubation Time	72 hours
Method	Exponentially growing cells are seeded in 96-well plastic plates and exposed to serial dilutions of erlotinib, pemetrexed, or the combination at a constant concentration ratio of 4:1 in triplicates for 72 h. Cell viability is assayed by cell count and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Growth inhibition is expressed as the percentage of surviving cells in drug-treated versus PBS-treated control cells (which is considered as 100% viability). The IC50 value is the concentration resulting in 50% cell growth inhibition by a 72-h exposure to drug(s) compared with untreated control cells and is calculated by the CalcuSyn software.

Animal Study: ^[6]

Animal Models	Male 5-week-old BALB-nu/nu with HPAC cells
Formulation	6% Captisol
Dosages	50 mg/kg
Administration	Oral administration

References

Chemical Information

Download Erlotinib HCl SDF

Molecular Weight (MW)	429.90
Formula	C₂₂H₂₃N₃O₄.HCl
CAS No.	183319-69-9
Synonyms	Tarceva

Solubility (25°C) DMSO 3 mg/mL Water <1 mg/mL Ethanol <1 mg/mL
Storage	2 years -20°CPowder
	2 weeks4°Cin DMSO
	6 months-80°Cin DMSO

Chemical Name	N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride

Molarity Calculator Dilution Calculator Molecular Weight Calculator

Research Area

Customer Reviews (12)

Click to enlarge

Rating

Source

Translational Oncology, 2011, 4, 92-100. Erlotinib HCl purchased from Selleck

Method

Western Blot

Cell Lines

Hs683 cells

Concentrations

10 μM

Incubation Time

4 d

Results

Figure 4 shows that AZD0530 prevented TMZ-induced soluble caveolin-1 expression but did not change basal levels of soluble caveolin-1 in Hs683 GBM cells. In contrast, erlotinib increased soluble caveolin-1 expression to a similar degree as TMZ in these Hs683 GBM cells.

Click to enlarge

Rating

Source

Head Neck, 2013, 35(1), 86-93.?. Erlotinib HCl purchased from Selleck

Method

MTT assays

Cell Lines

MET1 cells/MET1 cells/MET4 cells/SCC12 cells/SCC13 cells

Concentrations

0-2000 nM

Incubation Time

48 h

Results

Both erlotinib (Figure A) and PPP (Figure B) demonstrated dose-dependent decreases in cellproliferation with increasing concentrations. Next, all cell lines were cultured for 48 hours with varying concentrations of both erlotinib and PPP in combination (Figures C-F). In all cases, both erlotinib and PPP showed dose-dependent decreases in cell proliferation.

Click to enlarge

Rating

Source

J Immunother, 2011, 34(4), 372-81.. Erlotinib HCl purchased from Selleck

Method

Cytotoxicity assay

Cell Lines

NK-92 cells/ lung cancer cells

Concentrations

10 μM

Incubation Time

24 h

Results

Susceptibility of lung cancer cells to cytolytic activity of NK cells was significantly increased by treatment with EGFR inhibitors (erlotinib/gefitinib) and was reversed by blocking step using mAb against NKG2D before the assay in all lung cancer cells.

Click to enlarge

Rating

Source

J Clin Invest, 2012, 122(9), 3197-210.. Erlotinib HCl purchased from Selleck

Method

Relative growth assay

Cell Lines

HME1 cell

Concentrations

0-0.4 μM

Incubation Time

7 d

Results

FAM83B-expressing cells had sustained ERK1/2 phosphorylation and enhanced proliferation in the pres ence of EGFR-TKIs (AG1478, erlotinib, and CL387785) compared with control cells. In addition, FAM83B-expressing cells also grew significantly better than control cells after growth factor withdrawal.

Click to enlarge

Rating

Source

Microvasc. Res, 2010, 81, 135-142. Erlotinib HCl purchased from Selleck

Method

Myogenic tone of mice coronary arterioles

Cell Lines

Coronary arterioles

Concentrations

1 μM

Incubation Time

Results

In freshly isolated and mounted coronary arterioles in arteriograph, stepwise-increased intraluminal pressure induced myogenic tone development, which was significantly inhibited when the coronary arterioles we repretreated with EGFR tyrosine kinase inhibitor (AG1478, 1 μ M). Similar results were obtained using another EGFR tyrosine kinase inhibitor (Erlotininb, 1 μM)

Click to enlarge

Rating

Source

Dr Zhang of Tianjin Medical University. Erlotinib HCl purchased from Selleck

Method

Western blot

Cell Lines

Breast cancer cells

Concentrations

0-5 nM

Incubation Time

24 h

Results

Click to enlarge

Rating

Source

Int J Proteomics , 2011, 2011, Article ID 215496. Erlotinib HCl purchased from Selleck

Method

Nikon inverted-phase microscope

Cell Lines

lung tumor cell lines

Concentrations

0.1-1 μM

Incubation Time

Results

Erlotinib, which inhibited the growth of HCC827 cells cultured in anchorage-dependent cell culture plates, was also able to reduce the size of the cell colonies grown in agar plates in an anchorage-independent fashion. Similarly, reduction of cell colony size for mation was also observed by the treatment with the irreversible HER1/2 inhibitor BIBW-2992 in H1975 and H1650 cells as seen when these cell s were grown in an anchorage-dependent manner.

Click to enlarge

Rating

Source

Dr Balazs Halmos of Columbia University. Erlotinib HCl purchased from Selleck

Method

Western blot

Cell Lines

HCC827 cells, H1975 cells, H441 cells

Concentrations

1 μM

Incubation Time

Results

Click to enlarge

Rating

Source

Dr Balazs Halmos of Columbia University. Erlotinib HCl purchased from Selleck

Method

Real-time PCR analysis

Cell Lines

HCC827 cells, PC9 cells

Concentrations

Incubation Time

0-12 h

Results

Click to enlarge

Rating

Source

Carcinogenesis, 2010, 31, 1948–1955. Erlotinib HCl purchased from Selleck

Method

Luciferase assay

Cell Lines

LNCaP-AI cells, LNCaP cells

Concentrations

20 μM

Incubation Time

24 h

Results

EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Erlotinib and other inhibitors tested all downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells)

Click to enlarge

Rating

Source

Oncogene, 2010, 30, 2547-2557. Erlotinib HCl purchased from Selleck

Method

Western blot

Cell Lines

MCF7-HER2 cells

Concentrations

500 nM

Incubation Time

24 h

Results

we assessed whet her erlotinib, a TKI with selectivity for EGFR, could prevent the BEZ 235-induced increase of P-ERK. At 500 nM, erlotinib markedly reduced P-EGFR without affecting BEZ235-dependent P-ERK activation.

Click to enlarge

Rating

Source

Carcinogenesis, 2010, 31, 1948–1955. Erlotinib HCl purchased from Selleck

Method

ELISA

Cell Lines

LNCaP-AI cells

Concentrations

20 μM

Incubation Time

24 h

Results

Lapatinib, LY294002 and Bortezomib significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells .

Product Citations (21)

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. [Zhang Z, et al. Nat Genet 2012;44(8):852-60]
PubMed: 22751098
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. [Huang S, et al. Cell 2012;151(5):937-50]
PubMed: 23178117
FAM83B mediates EGFR-and RAS-driven oncogenic transformation. [Cipriano R, et al. J Clin Invest 2012;122(9):3197-210]
PubMed: 22886302

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. [Serra V, et al. Oncogene 2011;30(22), 2547-2557]
PubMed: 21278786
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib [Ezzoukhry Z, et al. Int J Cancer 2012;131(12):2961-9]
PubMed: 22514082
The intrinsic fusogenicity of glioma cells as a factor of transformation and progression in the tumor microenvironment. [Mercapide J, et al. Int J Cancer 2012;131(2):334-43]
PubMed: 21858806
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. [Zhang Z, et al. Carcinogenesis 2010;31(4), 577-586]
PubMed: 20097731
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. [Dong Z, et al. Carcinogenesis 2010;31(11), 1948-1955]
PubMed: 20837598
An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. [Winter GE, et al. Mol Cancer Ther 2011;10(10), 1846-1856]
PubMed: 21768330
Signatures of drug sensitivity in nonsmall cell lung cancer. [Gong HC, et al. Int J Proteomics 2011;2011, 215496]
PubMed: 22091388
Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. [Nie F, et al. Cancer 2012;118(21):5198-209]
PubMed: 22510844
An In Vivo C. elegans Model System for Screening EGFR-Inhibiting Anti-Cancer Drugs. [Bae YK, et al. PLoS One 2012;7(9):e42441]
PubMed: 22957020
Combination erlotinib-cisplatin and atg3-mediated autophagy in erlotinib resistant lung cancer. [Lee JG, et al. PLoS One 2012;7(10):e48532]
PubMed: 23119048
Intravitreal injection of TIMP3 or the EGFR inhibitor Erlotinib offers protection from oxygen-induced retinopathy in mice. [Hewing NJ, et al. Invest Ophthalmol Vis Sci 2013;54(1):864-70]
PubMed: 23299479
Temozolomide modifies caveolin-2 expression in experimental malignant gliomas in vitro and in vivo. [Bruyère C, et al. Transl Oncol 2011;4(2):92-100]
PubMed: 21461172
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. [Bae JH, et al. Cancer Sci 2012;103(1):7-16]
PubMed: 21951556
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. [Kim H, et al. J Immunother 2011;34(4):372-81]
PubMed: 21499124
Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity. [Gottschalk N, et al. Int J Mol Sci 2012;13(9):12000-16]
PubMed: 23109896
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality. [Clayburgh DR, et al. Head Nec 2013;35(1):86-93]
PubMed: 22495823
Mechanisms of myogenic tone of coronary arteriole: Role of down stream signaling of the EGFR tyrosine kinase. [Amin AH, et al. Microvasc Res 2011;81(1), 135-142]
PubMed: 21067705
Study of molecular mechanisms of sensitivity and resistance to EGFR-targeted therapy in lung cancer. [Zhang Z. Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy 2010;]

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3Monday–Friday 9:00 AM–5:00 PM (Central Time)

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Inhibitors

ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively.
Afatinib (BIBW2992)

BIBW2992 (Afatinib, Tomtovok, Tovok) irreversibly inhibits EGFR/HER2 including EGFR^wt, EGFR^L858R, EGFR^L858R/T790M and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively.
CI-1033 (Canertinib)

CI-1033 is a potent inhibitor of EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, respectively.
PI-103

PI-103 is a potent, ATP-competitive PI3K inhibitor of DNA-PK, p110α, mTORC1, PI3KC2β, p110δ, mTORC2, p110β, and p110γ with IC50 of 2 nM, 8 nM, 20 nM, 26 nM, 48 nM, 83 nM, 88 nM and 150 nM, respectively.
Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with K_i of 140 nM.
BMS-599626 (AC480)

BMS-599626 (AC480) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, respectively.
Obatoclax mesylate (GX15-070)

Obatoclax (GX15-070) is an inhibitor of Bcl-2 with K_i of 0.22 μM.
PD153035 HCl

PD153035 is a potent and specific inhibitor of EGFR with K_i and IC50 of 5.2 pM and 29 pM, respectively.
XL647
XL647 is a novel spectrum-selective kinase inhibitor for EGFR, ErbB2, KDR, Flt-4 and EphB4 with IC50 of 0.3 nM, 16 nM, 1.5 nM, 8.7 nM and 1.4 nM, respectively.
LY294002

LY294002 is a PI3K inhibitor for p110α, p110δ and p110β with IC50 of 0.5 μM, 0.57 μM and 0.97 μM, respectively.

RTKs and Angiogenesis Related Products

> Download

Erlotinib HCl + Everolimus(RAD001)	In NCI-H720 AC and SHP-77 LCNEC cells, Erlotinib HCl combined with Everolimus produces synergistic effects on induction of caspase-3-dependent apoptosis and leads to synergistic inhibition of EGFR/AKT/mTOR pathway. ^[7]
Erlotinib HCl + Rapamycin	In cell lines derived from a variety of tissue types (non-small-cell lung, pancreatic, colon, and breast), combination of Erlotinib HCl and Rapamycin results in a synergistic inhibition effect on cell growth by inhibition of both S6 and Akt. In a Calu6 xenograft model, Rapamycin and Erlotinib HCl combination shows synergistic effects in inhibiting tumor growth. ^[6]

Choose Your Country or Region

Product Categories

Erlotinib HCl

Validation & Quality Control

Product Citations(21)

Customer Reviews(12) in vivo invitation

Quality Control & MSDS

Related Compound Libraries

Erlotinib HCl is available in the following compound libraries:

Product Information

Compare EGFR Inhibitors

Research Area

Combination Therapy

Product Description

Biological Activity

Protocol(Only for Reference)

Kinase Assay: ^[1]

Cell Assay: ^[2]

Animal Study: ^[6]

References

Chemical Information

Research Area

Customer Reviews (12)

Product Citations (21)

Tech Support & FAQs

If you have any other enquiries, please leave a message.

Related EGFR Inhibitors

RTKs and Angiogenesis Related Products

Recently Viewed Items

Cat.No.	Product Name	Solubility (25°C)
Cat.No.	Product Name	Water	DMSO	Ethanol
S1023	Erlotinib HCl	<1 mg/mL	3 mg/mL	<1 mg/mL
S1025	Gefitinib (Iressa)	<1 mg/mL	89 mg/mL	4 mg/mL
S1028	Lapatinib Ditosylate (Tykerb)	<1 mg/mL	185 mg/mL	<1 mg/mL
S1011	Afatinib (BIBW2992)	<1 mg/mL	97 mg/mL	15 mg/mL
S1143	AG-490	<1 mg/mL	59 mg/mL	6 mg/mL
S2111	Lapatinib	<1 mg/mL	100 mg/mL	<1 mg/mL
S1167	CP-724714	<1 mg/mL	94 mg/mL	94 mg/mL
S2727	Dacomitinib (PF299804,PF-00299804)	<1 mg/mL	19 mg/mL	<1 mg/mL
S2728	AG-1478 (Tyrphostin AG-1478)	<1 mg/mL	25 mg/mL	13 mg/mL
S1019	CI-1033 (Canertinib)	<1 mg/mL	2 mg/mL	9 mg/mL
S1194	CUDC-101	<1 mg/mL	20 mg/mL	<1 mg/mL
S2150	Neratinib (HKI-272)	<1 mg/mL	2 mg/mL	<1 mg/mL
S1173	WZ4002	<1 mg/mL	13 mg/mL	<1 mg/mL
S1392	Pelitinib (EKB-569)	<1 mg/mL	13 mg/mL	<1 mg/mL
S2192	AZD8931	<1 mg/mL	40 mg/mL	<1 mg/mL
S2185	AST-1306	<1 mg/mL	124 mg/mL	<1 mg/mL
S2752	Arry-380	<1 mg/mL	114 mg/mL	<1 mg/mL
S1079	PD153035 HCl	<1 mg/mL	0.5 mg/mL	<1 mg/mL
S2755	ARRY334543	<1 mg/mL	6 mg/mL	<1 mg/mL
S2867	WHI-P154	<1 mg/mL	75 mg/mL	<1 mg/mL
S1179	WZ8040	<1 mg/mL	96 mg/mL	3 mg/mL
S2205	OSI-420	2 mg/mL	83 mg/mL	<1 mg/mL
S1056	BMS-599626 (AC480)	<1 mg/mL	113 mg/mL	20 mg/mL
S1486	AEE788 (NVP-AEE788)	<1 mg/mL	88 mg/mL	<1 mg/mL
S2784	TAK-285	<1 mg/mL	110 mg/mL	54 mg/mL
S2826	Desmethyl Erlotinib (CP-473420)	<1 mg/mL	11 mg/mL	5 mg/mL
S8009	AG 18 (Tyrphostin 23)	<1 mg/mL	37 mg/mL	37 mg/mL
S1170	WZ3146	<1 mg/mL	93 mg/mL	<1 mg/mL
S2895	Tyrphostin 9 (SF 6847)	<1 mg/mL	56 mg/mL	56 mg/mL
S2922	Icotinib	<1 mg/mL	78 mg/mL	7 mg/mL
S7039	PD168393	<1 mg/mL	74 mg/mL	<1 mg/mL

Choose Your Country or Region

Product Categories

Erlotinib HCl

Validation & Quality Control

Product Citations(21)

Customer Reviews(12) in vivo invitation

Quality Control & MSDS

Related Compound Libraries

Erlotinib HCl is available in the following compound libraries:

Product Information

Compare EGFR Inhibitors

Research Area

Combination Therapy

Product Description

Biological Activity

Protocol(Only for Reference)

Kinase Assay: [1]

Cell Assay: [2]

Animal Study: [6]

References

Chemical Information

Research Area

Customer Reviews (12)

Product Citations (21)

Tech Support & FAQs

If you have any other enquiries, please leave a message.

Related EGFR Inhibitors

RTKs and Angiogenesis Related Products

Recently Viewed Items

E-newsletter

Kinase Assay: ^[1]

Cell Assay: ^[2]

Animal Study: ^[6]